CoChat

Assessing the Future of Solid Tumor Immunotherapy

Open access

The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.

Abstract

With the advent of cancer immunotherapy, there has been a major improvement in patient's quality of life and survival. The growth of cancer immunotherapy has dramatically changed our understanding of the basics of cancer biology and has altered the standards of care (surgery, radiotherapy, and chemotherapy) for patients. Cancer immunotherapy has generated significant excitement with the success of chimeric antigen receptor (CAR) T cell therapy in particular. Clinical results using CAR-T for hematological malignancies have led to the approval of four CD19-targeted and one B-cell maturation antigen (BCMA)-targeted cell therapy products by the US Food and Drug Administration (FDA). Also, immune checkpoint inhibitors such as antibodies against Programmed Cell Death-1 (PD-1), Programmed Cell Death Ligand-1 (PD-L1), and Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4) have shown promising therapeutic outcomes and long-lasting clinical effect in several tumor types and patients who are refractory to other treatments. Despite these promising results, the success of cancer immunotherapy in solid tumors has been limited due to several barriers, which include immunosuppressive tumor microenvironment (TME), inefficient trafficking, and heterogeneity of tumor antigens. This is further compounded by the high intra-tumoral pressure of solid tumors, which presents an additional challenge to successfully delivering treatments to solid tumors. In this review, we will outline and propose specific approaches that may overcome these immunological and physical barriers to improve the outcomes in solid tumor patients receiving immunotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines10030655

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Adoptive cell transfer from patient tumor or blood. (1) Production begins with isolation of peripheral blood mononuclear cells (PBMC) from leukapheresis or tumor is excised and multiple individual cultures are isolated and (2) plated separately followed by (3) selection and activation of T cells. (4) T cells then undergo genetic modification for generating CAR-T cells or tumor cultures are assayed for specific tumor recognition. (5) Cells are expanded in presence of interleukins and when desired dose cell numbers are achieved, expanded cells are harvested and dose is formulated. (6) QC tests are performed to ensure that drug meets release criteria and is then fused into patients with or without conditioning lymphodepleting chemotherapy (6).
Figure 1 Adoptive cell transfer from patient tumor or blood. (1) Production begins with isolation of peripheral blood mononuclear cells (PBMC) from leukapheresis or tumor is excised and multiple individual cultures are isolated and (2) plated separately followed by (3) selection and activation of T cells. (4) T cells then undergo genetic modification for generating CAR-T cells or tumor cultures are assayed for specific tumor recognition. (5) Cells are expanded in presence of interleukins and when desired dose cell numbers are achieved, expanded cells are harvested and dose is formulated. (6) QC tests are performed to ensure that drug meets release criteria and is then fused into patients with or without conditioning lymphodepleting chemotherapy (6).CC BY · PubMed Central
Figure 2 Four generations of CAR-T cells. First generation CARs comprise of single chain variable fragment (scFv) antibody (orange) fused to transmembrane domain (purple) to TCR signaling component of CD3ζ (green) at the cytoplasmic tail. Second generation CARs have a CD28 co-stimulatory signaling domain (red) which enhances proliferation and cytotoxicity. Third generation CARs contain an additional co-stimulatory domain, 4-1BB (blue) to the second generation CARs which enhances proliferation, minimizes T cell exhaustion and improves CAR-T cells persistence. Fourth generation CARs also called “T cell directed for universal cytokine-mediated killing” (TRUCKs) are engineered to secrete cytokines (gray) to attract immune cells (NK and macrophages).
Figure 2 Four generations of CAR-T cells. First generation CARs comprise of single chain variable fragment (scFv) antibody (orange) fused to transmembrane domain (purple) to TCR signaling component of CD3ζ (green) at the cytoplasmic tail. Second generation CARs have a CD28 co-stimulatory signaling domain (red) which enhances proliferation and cytotoxicity. Third generation CARs contain an additional co-stimulatory domain, 4-1BB (blue) to the second generation CARs which enhances proliferation, minimizes T cell exhaustion and improves CAR-T cells persistence. Fourth generation CARs also called “T cell directed for universal cytokine-mediated killing” (TRUCKs) are engineered to secrete cytokines (gray) to attract immune cells (NK and macrophages).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 130 references

Cited by

See all 105

Metadata

Authors
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S., & Katz, S. C.
Affiliations
  • Boston University (US)
  • Roger Williams Medical Center (US)
  • Northwestern University (US)
Corresponding author
Guha, Prajna
Venue
Biomedicines
Publisher
MDPI AG
Published
2022-03-11
Volume
10
Issue
3
Pages
655
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4220953090
Cited by
105
References
130
Citations by year
2026: 15 · 2025: 28 · 2024: 30 · 2023: 26 · 2022: 6
FWCI
2.75
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
solid tumor immunotherapy, CAR T-cell therapy, immune checkpoint inhibitors, PD-1, PD-L1, CTLA-4, immunosuppressive tumor microenvironment, tumor antigen heterogeneity, drug delivery barriers, BCMA

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessing the Future of Solid Tumor Immunotherapy. https://app.cochat.ai/papers/10.3390/biomedicines10030655
The paper
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S., & Katz, S. C. (2022). Assessing the Future of Solid Tumor Immunotherapy. Biomedicines. https://doi.org/10.3390/biomedicines10030655

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.